相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Fractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukemia salvage in patients aged 50-70-year old: A phase 1/2 study of the acute leukemia French association
Hassan Farhat et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications
Hsin-An Hou et al.
BLOOD (2012)
Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML
Jessica A. Pollard et al.
BLOOD (2012)
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
Sylvie Castaigne et al.
LANCET (2012)
Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity?
Brunangelo Falini et al.
BLOOD (2011)
Coexistence of LMPP-like and GMP-like Leukemia Stem Cells in Acute Myeloid Leukemia
Nicolas Goardon et al.
CANCER CELL (2011)
Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and resistance, safety and efficacy
Massimo Breccia et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2011)
Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial
Alan K. Burnett et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Mutant nucleophosmin and cooperating pathways drive leukemia initiation and progression in mice
George S. Vassiliou et al.
NATURE GENETICS (2011)
Stem cell gene expression programs influence clinical outcome in human leukemia
Kolja Eppert et al.
NATURE MEDICINE (2011)
Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells
R. Majeti
ONCOGENE (2011)
Targeted Drug Delivery by Gemtuzumab Ozogamicin: Mechanism-Based Mathematical Model for Treatment Strategy Improvement and Therapy Individualization
Eva Jager et al.
PLOS ONE (2011)
High-frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicine
Costa Bachas et al.
BLOOD (2010)
Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34- fraction
David C. Taussig et al.
BLOOD (2010)
Analysis of factors that affect in vitro chemosensitivity of leukaemic stem and progenitor cells to gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukaemia
M. Jawad et al.
LEUKEMIA (2010)
Identification of a myeloid committed progenitor as the cancer-initiating cell in acute promyelocytic leukemia
Florence C. Guibal et al.
BLOOD (2009)
Effective Treatment of Acute Promyelocytic Leukemia With All-Trans-Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin
Farhad Ravandi et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
A robust xenotransplantation model for acute myeloid leukemia
P. V. Sanchez et al.
LEUKEMIA (2009)
Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells
David C. Taussig et al.
BLOOD (2008)
Malignant transformation initiated by MII-AF9: Gene dosage and critical target cells
Weili Chen et al.
CANCER CELL (2008)
Modeling of C/EBP alpha mutant acute myeloid leukemia reveals a common expression signature of committed myeloid leukemia-initiating cells
Peggy Kirstetter et al.
CANCER CELL (2008)
Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia
Roberto Stasi et al.
CANCER TREATMENT REVIEWS (2008)
Large interindividual differences in cellular sensitivity to calicheamicin may influence gemtuzumab ozogamicin response in acute myeloid leukemia
B. F. Goemans et al.
LEUKEMIA (2008)
Complementing mutations in core binding factor leukemias:: from mouse models to clinical applications
Ams Mueller et al.
ONCOGENE (2008)
Therapeutic implications of leukemia stem cell development
Matthew C. Stubbs et al.
CLINICAL CANCER RESEARCH (2007)
CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy
Roland B. Walter et al.
BLOOD (2007)
The role of Gemtuzumab Ozogamicin in the treatment of acute myeloid leukemia patients
L. Pagano et al.
ONCOGENE (2007)
Expression of the target receptor CD33 in CD34(+)/CD38(-)/CD123(+) AML stem cells
A. W. Hauswirth et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2007)
Sustained molecular remission after low dose gemtuzumab-ozogamicin in elderly patients with advanced acute promyelocytic leukemia
Massimo Breccia et al.
HAEMATOLOGICA (2007)
High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group
A-L Taksin et al.
LEUKEMIA (2007)
X-linked clonality testing: interpretation and limitations
George L. Chen et al.
BLOOD (2007)
FLT3 internal tandem duplication in CD34+/CD33- precursors predicts poor outcome in acute myeloid leukemia
Jessica A. Pollard et al.
BLOOD (2006)
Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia
Tim C. P. Somervaille et al.
CANCER CELL (2006)
Monoclonal antibodies for the treatment of acute myeloid leukemia
Syed A. Abutalib et al.
CURRENT PHARMACEUTICAL BIOTECHNOLOGY (2006)
Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9
Andrei V. Krivtsov et al.
NATURE (2006)
A murine Mll-AF4 knock-in model results in lymphoid and myeloid deregulation and hematologic malignancy
Weili Chen et al.
BLOOD (2006)
AML patients with CEBPα mutations mostly retain identical mutant patterns but frequently change in allelic distribution at relapse:: a comparative analysis on paired diagnosis and relapse samples
LY Shih et al.
LEUKEMIA (2006)
AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML
DJ Pearce et al.
BLOOD (2006)
Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia
DC Taussig et al.
BLOOD (2005)
Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence
RA Larson et al.
CANCER (2005)
Genetics of myeloid malignancies:: Pathogenetic and clinical implications
S Fröhling et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity
RB Walter et al.
BLOOD (2005)
CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance
ML Linenberger
LEUKEMIA (2005)
AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia:: Implication in stepwise leukemogenesis and response to Gleevec
YY Wang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Gemtuzumab ozogamicin: A review of its use in acute myeloid leukaemia
C Fenton et al.
DRUGS (2005)
Arming antibodies: prospects and challenges for immunoconjugates
AM Wu et al.
NATURE BIOTECHNOLOGY (2005)
Acute promyelocytic leukemia: where does it stem from?
D Grimwade et al.
LEUKEMIA (2004)
Heterogeneous patterns of FLT3 ASP835 mutations in relapsed de novo acute myeloid leukemia:: A comparative analysis of 120 paired diagnostic and relapse bone marrow samples
LY Shih et al.
CLINICAL CANCER RESEARCH (2004)
Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity
I Jedema et al.
LEUKEMIA (2004)
Mechanisms controlling pathogenesis and survival of leukemic stem cells
CT Jordan et al.
ONCOGENE (2004)
Brief report - Mutation of CEBPA in familial acute myeloid leukemia
ML Smith et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors
BJP Huntly et al.
CANCER CELL (2004)
High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg®) treatment in acute myeloid leukemia patients
VHJ van der Velden et al.
LEUKEMIA (2004)
Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia
F Lo-Coco et al.
BLOOD (2004)
Engraftment of acute myeloid leukemia in NOD/SCID mice is independent of CXCR4 and predicts poor patient survival
G Monaco et al.
STEM CELLS (2004)
Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors
A Cozzio et al.
GENES & DEVELOPMENT (2003)
Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia
F Giles et al.
CANCER (2003)
Normal and leukemic hematopoiesis:: Are leukemias a stem cell disorder or a reacquisition of stem cell characteristics?
E Passegué et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells
RB Walter et al.
BLOOD (2003)
Anti body-targeted chemotherapy with immunoconjugates of calicheamicin
NK Damle et al.
CURRENT OPINION IN PHARMACOLOGY (2003)
MLL-GAS7 transforms multipotent hematopoietic progenitors and induces mixed lineage leukemias in mice
CW So et al.
CANCER CELL (2003)
Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia:: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors
PD Kottaridis et al.
BLOOD (2002)
Differences in CD33 intensity between various myeloid neoplasms
I Jilani et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2002)
Human AML cells in NOD/SCID mice: engraftment potential and gene expression
R Lumkul et al.
LEUKEMIA (2002)
Experience with gemtuzumab ozogamycin (mylotarg), and all-trans retinoic acid in untreated acute promyelocytic leukemia
EH Estey et al.
BLOOD (2002)
In utero origin of t(8;21) AML1-ETO translocations in childhood acute myeloid leukemia
JL Wiemels et al.
BLOOD (2002)
An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker
PR Hamann et al.
BIOCONJUGATE CHEMISTRY (2002)
Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia
PR Hamann et al.
BIOCONJUGATE CHEMISTRY (2002)
Stem cells, cancer, and cancer stem cells
T Reya et al.
NATURE (2001)
Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse
EL Sievers et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells
VHJ van der Velden et al.
BLOOD (2001)
Differential responses of Chinese hamster mutagen sensitive cell lines to low and high concentrations of calicheamicin and neocarzinostatin
A van Duijn-Goedhart et al.
MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS (2000)
AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation
T Miyamoto et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Identification of variables determining the engraftment potential of human acute myeloid leukemia in the immunodeficient NOD/SCID human chimera model
WJC Rombouts et al.
LEUKEMIA (2000)
Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene
WJC Rombouts et al.
LEUKEMIA (2000)
Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate
ID Bernstein
LEUKEMIA (2000)
分享论文
